BioNet - Broadly Protective Coronavirus Vaccine
- Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
- Total publications:1000 publications
Grant number: N/A
Grant search
Key facts
Disease
COVID-19start year
2022Known Financial Commitments (USD)
$16,900,000Funder
Coalition for Epidemic Preparedness Innovations (CEPI)Principal Investigator
N/A
Research Location
FranceLead Research Institution
BioNetResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Pre-clinical studies
Special Interest Tags
N/A
Study Type
Not applicable
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched in March 2021, to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other Betacoronaviruses.1 CEPI will partner with BioNet'Äîa French-Thai vaccine manufacturer and member of the Developing Country Vaccine Manufacturing network (DCVMN)'Äîproviding up to $16.9 million to support preclinical studies, Phase I and Phase II clinical trials, production of necessary clinical trial material, and process and analytical development.
Publicationslinked via Europe PMC
Last Updated:2 hours ago
View all publications at Europe PMC